An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

M. Agulnik*, J. L. Yarber, S. H. Okuno, M. von Mehren, B. D. Jovanovic, B. E. Brockstein, A. M. Evens, R. S. Benjamin

*Corresponding author for this work

Research output: Contribution to journalArticle

186 Scopus citations


Background: To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Patients and methods: In this single-arm phase II trial, 32 patients were enrolled and they received bevacizumab 15 mg/kg IV infusion in 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status of <1, adequate organ function and had not received any radiation treatment in the last 28 days. Results: Of the 30 patients evaluated for efficacy and toxic effect, four (two angiosarcoma and two epithelioid hemangioendothelioma; 17%) had a partial response. Fifteen patients (11 angiosarcoma and 4 epithelioid hemangioendothelioma; 50%) showed stable disease with a mean time to progression of 26 weeks. Bevacizumab was well tolerated with only one grade 4 adverse event. Expected known toxic effects of the drug were manageable. Conclusion: Bevacizumab is an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Further phase III studies of bevacizumab in combination with other chemotherapeutic agents and/or radiation treatment are warranted.

Original languageEnglish (US)
Article numbermds237
Pages (from-to)257-263
Number of pages7
JournalAnnals of Oncology
Issue number1
StatePublished - Jan 1 2013



  • Angiosarcoma
  • Bevacizumab
  • Hemangioendotheliomas
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this